Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

Abstract Background Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-line treatment of ES-SCLC. This retrospective multice...

Full description

Bibliographic Details
Main Authors: Boyu Qin, Lingli Xin, Chen Liang, Lingling Li, Qi Song, Yaping Long, Xiaoling Zhang, Dan Wang, Weiwei Shi, Jing Zhang, Yi Hu, Bo Yang, Qi Xiong
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Small cell lung cancer
Anti-PD-1/PD-L1
Immunotherapy
Locoregional thoracic radiotherapy
Lactate dehydrogenase
Online Access:https://doi.org/10.1186/s12885-024-11833-6

Internet

https://doi.org/10.1186/s12885-024-11833-6

Similar Items